Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 94. (Canceled)

95. (New) A crystal of infliximab, wherein the crystal comprises infliximab, ethoxyethanol, lithium sulfate, and Tris buffer.

96. (New) The crystal of claim 95, wherein the pH is 8.6.

97. (New) A method of crystallizing infliximab, the method comprising:

combining infliximab, ethoxyethanol, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

98. (New) The method of claim 97, wherein the method is performed at room temperature.

99. (New) The method of claim 97, wherein the method is performed at pH 8.6.

100. (New) The method of claim 97, wherein the concentration of infliximab in the crystallization solution is 16.67 mg/ml.

101. (New) The method of claim 97, wherein the percentage of ethoxyethanol in the crystallization solution is 23.3%.

102. (New) The method of claim 97, wherein the concentration of lithium sulfate in the crystallization solution is 0.13 M.

103. (New) The method of claim 97, wherein the concentration of Tris buffer in the crystallization solution is 0.067 M.

104. (New) The method of claim 97, wherein the concentration of infliximab in the crystallization solution is 16.67 mg/ml, the percentage of ethoxyethanol in the crystallization solution is 23.3%, the concentration of lithium sulfate in the crystallization solution is 0.13 M, and the concentration of Tris buffer in the crystallization solution is 0.067 M.

105. (New) A crystal of infliximab, wherein the crystal comprises infliximab, PEG-400, lithium sulfate, and Tris buffer.

106. (New) The crystal of claim 105, wherein the pH is 8.5.

107. (New) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG-400, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

108. (New) The method of claim 107, wherein the method is performed at room temperature.

109. (New) The method of claim 107, wherein the method is performed at pH 8.5.

110. (New) The method of claim 107, wherein the concentration of infliximab in the crystallization solution is 16.67 mg/ml.

111. (New) The method of claim 107, wherein the percentage of PEG-400 in the crystallization solution is 26.67%.

112. (New) The method of claim 107, wherein the concentration of lithium sulfate in the crystallization solution is 0.13 M.

113. (New) The method of claim 107, wherein the concentration of Tris buffer in the crystallization solution is 0.067 M.

114. (New) The method of claim 107, wherein the concentration of infliximab in the crystallization solution is 16.67 mg/ml, the percentage of PEG-400 in the crystallization solution is 26.67%, the concentration of lithium sulfate in the crystallization solution is 0.13 M, and the concentration of Tris buffer in the crystallization solution is 0.067 M.

115. (New) A crystal of infliximab, wherein the crystal comprises infliximab, polyethylene glycol monomethyl ether 550 (PEG MME 550), calcium chloride, and Tris HCl buffer.

116. (New) The crystal of claim 115, wherein the pH of the Tris HCl buffer is 7.0.

117. (New) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG MME 550, calcium chloride, and Tris HCl buffer, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

118. (New) The method of claim 117, wherein the method is performed at room temperature.

119. (New) The method of claim 117, wherein the pH of the Tris HCl buffer is 7.0.

120. (New) The method of claim 117, wherein the concentration of infliximab in the crystallization solution is 37.88 mg/ml.

121. (New) The method of claim 117, wherein the percentage of PEG MME 550 in the crystallization solution is 15.15%.

122. (New) The method of claim 117, wherein the concentration of calcium chloride in the crystallization solution is 0.091 M.

123. (New) The method of claim 117, wherein the concentration of Tris HCl buffer in the crystallization solution is 0.076 M.

124. (New) The method of claim 117, wherein the concentration of infliximab in the crystallization solution is 37.88 mg/ml, the percentage of PEG MME 550 in the crystallization solution is 15.15%, the concentration of calcium chloride in the crystallization solution is 0.091 M, and the concentration of Tris HCl buffer in the crystallization solution is 0.076 M.

125. (New) A crystal of infliximab, wherein the crystal comprises infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol.

126. (New) The crystal of claim 125, wherein the pH is 8.5.

127. (New) A method of crystallizing infliximab, the method comprising:

combining infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol, thereby forming a crystallization solution; and

incubating the crystallization solution, thereby crystallizing infliximab.

128. (New) The method of claim 127, wherein the method is performed at room temperature.

129. (New) The method of claim 127, wherein the pH is 8.5.

130. (New) The method of claim 127, wherein the concentration of infliximab in the crystallization solution is 6.67 mg/ml.

131. (New) The method of claim 127, wherein the percentage of PEG 300 in the crystallization solution is 13.3%.

132. (New) The method of claim 127, wherein the concentration of Tris buffer in the crystallization solution is 0.067 M.

133. (New) The method of claim 127, wherein the percentage of PEG 8000 in the crystallization solution is 3.33%.

134. (New) The method of claim 127, wherein the percentage of glycerol in the crystallization solution is 6.67%.

135. (New) The method of claim 127, wherein the concentration of infliximab in the crystallization solution is 6.67 mg/ml, the percentage of PEG 300 in the crystallization solution is 13.3%, the concentration of Tris buffer in the crystallization solution is 0.067 M, the percentage of PEG 8000 in the crystallization solution is 3.33%, and the percentage of glycerol in the crystallization solution is 6.67%.